Company / Working Capital
Compass Therapeutics, Inc. Working Capital History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$123.9M
FY2024
5-year range
$40.1M / $178.6M
FY2020-FY2024
Trend
-15.2%
vs FY2023
Sector context
#189 of 215
Health Care
What the data says
Compass Therapeutics, Inc.'s working capital of $124M is lower than 88% of companies in the Health Care sector (FY2024). Declined from $179M to $124M over the past 2 years.
Based on SEC 10-K filings.
$124M in FY2024 with a 5-year CAGR of +49.8%.
Declined from $179M to $124M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -3.2%
- 5-Year CAGR
- +49.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 215This company $123.9M Sector average $957.8M
▼
-87.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +49.8%, indicating consistent growth.
- In FY2024, working capital decreased 15.2% year-over-year.
- Ranks #189 out of 215 companies in the Health Care sector.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $123.9M | -15.2% |
| FY2023 | $146.1M | -18.2% |
| FY2022 | $178.6M | +30.9% |
| FY2021 | $136.5M | +240.3% |
| FY2020 | $40.1M | +144.3% |
| FY2019 | $16.4M | +47613.9% |
| FY2018 | -$34.6K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026